Monoclonal antibodies - A new era in the treatment of multiple myeloma
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
26362528
DOI
10.1016/j.blre.2015.08.004
PII: S0268-960X(15)00065-X
Knihovny.cz E-resources
- Keywords
- BHQ880, Bone disease, Daratumumab, Denosumab, Elotuzumab, Lorvotuzumab, Monoclonal antibodies, Multiple myeloma, Pembrolizumab, Siltuximab,
- MeSH
- Molecular Targeted Therapy MeSH
- Clinical Trials as Topic MeSH
- Humans MeSH
- Multiple Myeloma complications drug therapy mortality pathology MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Bone Diseases drug therapy etiology MeSH
- Antineoplastic Agents therapeutic use MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Antibodies, Monoclonal MeSH
- Antineoplastic Agents MeSH
Monoclonal antibodies (mAbs) are currently the most investigated therapeutic compounds in oncology, but there is no monoclonal antibody approved in the treatment of multiple myeloma (MM). Nevertheless several really promising molecules are under investigation in phase III clinical trials. Dominantly daratumumab (anti-CD38) and elotuzumab (anti-CS1) showed extraordinary effectiveness in phase I/II trials. The toxicity was acceptable which is important for their addition to standard anti-myeloma agents like proteasome inhibitors or immunomodulatory drugs. Monoclonal antibodies such as denosumab (anti-RANKL) or BHQ880 (anti-DKK-1) are investigated also in the management of myeloma bone disease. This review is focused on the most promising mAbs, their mechanisms of action and the rationale of use. Practically all available results have been described. If the ongoing trials confirm the efficacy and safety of mAbs, they would become an important part of MM treatment that would be translated in the further improvement of therapeutic outcomes.
References provided by Crossref.org
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease
Natural Killer Cells in the Malignant Niche of Multiple Myeloma
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
PD-1/PD-L1 inhibitors in haematological malignancies: update 2017
Current applications of multiparameter flow cytometry in plasma cell disorders
PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future
